[A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment]

Highly effective H. pylori eradication therapies are currently used in Japan. However, eradication failures still appear in a considerable proportion of cases. In such refractory cases, several second-line eradication therapies and therapeutic efficacies have been only exceptionally studied. Our aims were to analyze the reasons and evaluate the second-line therapies when first-line eradication therapies fail. We make a strategy for second-line anti-H. pylori therapy in patients with previously failed treatment.